Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Haplo-HSCT bests chemotherapy for MRD-positive adult ALL

Key clinical point: Haplo-HSCT outperforms chemotherapy in adults with acute lymphocytic leukemia in first complete remission.

Major finding: The 2-year leukemia-free survival was about 70% in patients in first remission who received haplo-HSCT vs. 40% in patients who received chemotherapy.

Study details: A prospective multicenter trial of 112 adult patients with acute lymphocytic leukemia.

Disclosures: Dr. Lv reported having no financial disclosures.

Citation:

Lv M et al. TCT 2019, Abstract 8.